Royalty Pharma plc
RPRX · XNASCIK 1802768fmd_0WBVQ94YS0JNMYNWMSMW94JJAMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 31 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,795 | 1,814 | 2,122 | 2,289 | 2,237 | 2,355 | 2,264 | 2,378 |
| Provision for credit losses | (57) | (1,019) | 231 | 453 | (194) | (22) | (100) | 26 |
| Research and development | 393 | 83 | 26 | 200 | 177 | 52 | 2 | 452 |
| Operating income | 1,364 | 2,623 | 1,595 | 1,431 | 307 | 1,492 | 1,292 | 1,560 |
| Interest expense | 280 | 269 | 157 | 166 | 188 | 187 | 226 | 308 |
| Other non-operating income (expense) | 153 | (162) | 107 | (190) | (77) | 208 | 38 | (235) |
| Income before taxes | 1,518 | 2,461 | 1,702 | 1,241 | 230 | 1,700 | 1,331 | 1,324 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1,518 | 2,461 | 1,702 | 1,241 | 230 | 1,700 | 1,331 | 1,324 |
| Net income | 1,378 | 2,349 | 975 | 620 | 43 | 1,135 | 859 | 771 |
| Net income to common shareholders | – | – | 495 | 620 | 43 | 1,135 | 859 | 771 |